Chiesi Australia Competitors and Similar CompaniesClear all

Chiesi Australia's competitors and similar companies include Clinigen, Boehringer Ingelheim Pharma, C.H. Boehringer Sohn and Purna Pharmaceuticals.

	Chiesi Australia Chiesi Australia is a pharmaceutical company that specializes in drug development.	Clinigen Clinigen is a specialist pharmaceutical services company.	Boehringer Ingelheim Pharma Boehringer Ingelheim Pharma is a research-based pharmaceutical company.	C.H. Boehringer Sohn C.H. Boehringer Sohn is a holding company engaged in pharma development.	Purna Pharmaceuticals Purna Pharmaceuticals is a developer, and manufacturer of pharmaceutical products.
Founding Date	Founding Date 1935	Founding Date 2010	Founding Date 1969	Founding Date 1885	Founding Date 1986
Type	Type Subsidiary	Type Private	Type Subsidiary	Type Private	Type Private
Tags	Tags Healthcare drug development pharma	Tags Manufacturing & Industrial clinical research drug development pharma	Tags Manufacturing & Industrial clinical research drug development pharma	Tags Manufacturing & Industrial clinical research drug development holding company pharma	Tags Manufacturing & Industrial clinical research drug development pharma
Locations	Locations Melbourne, AU HQ	Locations Burton upon Trent, GB HQ Warriewood, AU Lyon, FR Koropi, GR Lismore, IE Chuo City, JP Singapore, SG see more	Locations Ingelheim am Rhein, DE HQ	Locations Ingelheim am Rhein, DE HQ	Locations Puurs, BE HQ
Employees	Employees 433% increase	Employees 586	Employees 10,000	Employees 52,000	Employees 1442% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) £562.2m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) €19.6b (FY, 2020)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods £301.2m (FY, 2021)	Cost of goods N/A	Cost of goods €2.6b (FY, 2020)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit £261m (FY, 2021)	Gross profit N/A	Gross profit €17b (FY, 2020)	Gross profit N/A
Net income	Net income N/A	Net income £38.7m (FY, 2021)	Net income N/A	Net income €3.1b (FY, 2020)	Net income N/A